Rubric Capital Management (New York)’s Trevi Therapeutics TRVI Stock Holding History

Rubric Capital Management (New York)’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.3M	Sell	3,712,373 -54,376	-1%	-$609K	0.47%	45
2025 Q4	$47.2M	Sell	3,766,749 -4,765,111	-56%	-$55.1M	0.56%	47
2025 Q3	$78.1M	Hold	8,531,860	–	–	0.88%	30
2025 Q2	$46.7M	Buy	8,531,860 +3,993,325	+88%	+$24.8M	0.71%	36
2025 Q1	$28.5M	Buy	4,538,535 +333,406	+8%	+$1.59M	0.51%	40
2024 Q4	$17.3M	Sell	4,205,129 -821,802	-16%	-$2.63M	0.22%	50
2024 Q3	$16.8M	Hold	5,026,931	–	–	0.27%	48
2024 Q2	$15M	Sell	5,026,931 -537,192	-10%	-$1.49M	0.39%	50
2024 Q1	$19.2M	Sell	5,564,123 -120,297	-2%	-$268K	0.57%	48
2023 Q4	$7.62M	Hold	5,684,420	–	–	0.16%	48
2023 Q3	$12.4M	Hold	5,684,420	–	–	0.46%	47
2023 Q2	$13.6M	Hold	5,684,420	–	–	0.58%	42
2023 Q1	$10.5M	Hold	5,684,420	–	–	0.27%	54
2022 Q4	$11M	Hold	5,684,420	–	–	0.48%	53
2022 Q3	$8.75M	Buy	5,684,420 +3,906,000	+220%	+$12.8M	0.44%	49
2022 Q2	$5M	Buy	+1,778,420	New	+$4.37M	0.26%	61

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Rubric Capital Management (New York)'s TRVI Position: Q1 2026 in Review

Rubric Capital Management (New York) reduced its Trevi Therapeutics (TRVI) stake by 1.4% in Q1 2026, selling an estimated $609K and leaving 3,712,373 shares worth $44.3M. The position accounts for 0.47% of the portfolio, ranked #45.

Rubric Capital Management (New York) first reported a position in TRVI in Q2 2022 and has held it in 16 quarters since. The position peaked at $78.1M in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Rubric Capital Management (New York) held 3,712,373 shares of Trevi Therapeutics worth $44.3M as of Q1 2026.
Rubric Capital Management (New York) sold 54,376 Trevi Therapeutics shares in Q1 2026, an estimated $609K.
Trevi Therapeutics made up 0.47% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #45 holding.
Rubric Capital Management (New York) first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 16 quarters since.
Rubric Capital Management (New York)'s Trevi Therapeutics position peaked at $78.1M in Q3 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.